🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Alaunos Therapeutics, Inc. TCRT PHARMA

Healthcare · Biotechnology · United States
https://www.alaunos.com
Company Profile ↓
$1.57
-34.31% 1Y
Mkt Cap$3.99M
P/E-0.90
P/B2.21
52W High$4.36
52W Low$1.57
Book Value$0.54
EPS (TTM)$-1.75

Company Overview

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.00.

Recent Developments

  • Dec 2025 Revenue of $5.00K (-50.0% YoY); net profit $-4.18M.
  • Trailing 12 Months Year-on-year growth — revenue -50.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR -41.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-41.94%
1 Year:-50.00%

Stock Price Performance

1 Year:-34.31%
6 Months:-56.99%
3 Months:-21.50%
1 Month:-21.11%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$1.57 $4.36
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)29.42 · Oversold
Price Performance
1M-21.11%
3M-21.50%
6M-56.99%
1Y-34.31%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -41.9% CAGR over 5 years.
  • Trading 64.0% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.90
Industry PE
24.83
Forward P/E
-2.62
PEG Ratio
0.58
Book Value
$0.54
Price to Book
2.21
P/S
1,016.19
EV/EBITDA
-0.72
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-41.94%
Profit 5Y
-
Revenue (YoY)
-50.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-
ROA
-81.13%
Profit Margin
0.00%
Op Margin
-
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.59
EPS (TTM)
$-1.75

Balance Sheet & Liquidity

Debt/Equity
0.00
Quick Ratio
0.14
Current Ratio
0.77
Debt
$0
Total Assets
$1.88M
Current Assets
$970.00K
Working Capital
$1.18M

Ownership

Promoter Holding
15.30%
Chg in Prom Hold
-0.62%
FII / Inst Holding
4.88%
Chg in FII Hold
-0.20%

Financial Snapshot

Enterprise Value
$3.99M
Total Revenue (TTM)
$3.00K
EBITDA
$-4.03M
Free Cash Flow
$-1.57M
Operating Cash Flow
$-2.73M
Shares Outstanding
2.54M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TCRT Alaunos Therapeutics, Inc. PHARMA 1.57 -0.90 $3.99M 0.00% - - -41.94% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------1.60M1.60M1.60M1.60M146.00K000----0000--398.00K-02.91M04.00K01.00K4.00K0-2.00K003.00K0
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------1.09M1.04M1.19M910.00K1.01M
Operating Income -18.17M-9.48M-12.04M-131.24M-10.91M-11.11M-13.96M-13.01M-13.08M-13.44M-16.20M-12.38M-12.57M-12.76M-13.62M-14.75M-13.45M-16.04M-18.66M-18.61M-20.32M-22.77M-21.56M-22.64M-22.30M-9.09M-9.23M-8.26M-9.67M-7.98M-8.66M-1.74M-1.17M-1.15M--1.09M-1.04M-1.19M-907.00K-1.01M
EBITDA ------------------------------------1.09M-1.04M-1.19M-900.00K-1.00M
Interest Expense ----------------------------------0-----
Pretax Income ------------------------------------1.07M-1.05M-1.16M-893.00K-1.01M
Tax Provision ----------------------------------------
Net Income -18.17M-9.48M-12.02M-131.20M-14.45M-14.76M-19.66M-17.73M-17.60M-18.27M-21.14M-17.49M-18.66M194.54M-13.43M-14.62M-74.00M-15.75M-18.29M-18.60M-20.32M-22.77M-21.55M-22.67M-22.73M-9.79M-9.93M-8.85M-10.05M-8.77M-8.48M-1.68M-1.13M-1.13M--1.07M-1.05M-1.16M-893.00K-1.01M
Diluted EPS -----------0.15-0.12-0.131.29-0.08-0.09-0.43-0.09-0.09-0.09-0.10-0.11--0.11-0.11-0.05-0.05-0.04-0.63-5.49-5.30-1.05-0.71-0.70--0.67-0.63-0.55--0.59
R&D Expense 16.97M-10.20M129.23M8.97M-11.97M10.83M11.11M-10.18M7.49M8.26M-9.48M10.00M8.64M-12.71M12.05M13.97M-13.34M13.57M14.52M5.58M5.94M7.89M6.50M5.19M3.66M126.00K180.00K143.00K-347.00K185.00K469.00K-427.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------667.00K800.00K---6.86M6.39M146.00K-0-2.92M5.00K10.00K5.00K
Cost of Revenue ----------------------
Gross Profit ----------------------
Operating Expenses ------------------38.16M28.50M4.82M4.23M
Operating Income ------12.12M-24.55M-71.40M-102.17M-57.71M-43.50M-120.10M-165.31M-53.49M-53.91M-57.86M-80.36M--35.24M-28.49M-4.81M-4.22M
EBITDA -------------------31.82M-30.90M-4.81M-4.22M
Interest Expense -----------------1.19M3.15M1.92M0-
Pretax Income -------------------37.73M-35.14M-4.68M-4.18M
Tax Provision ----------------------
Net Income -5.69M-9.52M-17.86M-26.61M-25.23M-7.65M-32.67M-63.78M-96.13M-57.11M-31.78M-120.09M-165.30M-54.32M-53.12M-117.80M-79.98M--37.73M-35.14M-4.68M-4.18M
Diluted EPS -------------1.32-0.530.96-0.70-0.38--25.50-21.97-2.92-2.20
R&D Expense -----4.56M12.91M57.08M83.45M42.85M32.71M106.78M157.79M45.08M34.13M38.33M52.70M49.64M25.02M16.28M362.00K1.36M

Balance Sheet (Annual)

Figures in USD.

Metric Sep 2003Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --------61.52M108.11M83.40M71.75M45.24M153.72M106.35M105.61M95.05M109.11M146.34M-64.94M8.26M2.75M2.97M
Current Assets --------------------53.80M8.26M2.75M1.99M
Cash & Equivalents 0-----11.38M48.84M60.39M104.71M73.31M68.20M42.80M140.72M81.05M70.95M61.73M79.74M115.07M-39.06M6.06M1.09M1.39M
Inventory ------------------------
Receivables --------------------4.00K1.00K5.00K3.00K
Total Liabilities --------30.97M36.50M34.96M22.37M11.40M66.35M58.33M58.42M9.49M14.10M22.36M-26.38M1.96M692.00K813.00K
Current Liabilities --------3.61M13.36M18.86M7.79M10.83M18.12M15.81M20.86M9.48M12.53M18.37M-24.17M1.96M692.00K813.00K
Long Term Debt ------------------016.25M----
Total Debt -------------------29.36M19.51M0--
Total Equity 500.00K340.00K-144.00K7.20M26.53M30.37M6.74M28.10M30.55M71.61M48.45M49.38M33.84M87.37M-77.30M-96.81M85.56M95.01M123.98M-38.55M6.31M2.06M2.15M
Shares Outstanding --------------------1.60M1.60M1.60M2.35M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -12.29M-19.69M-38.84M-78.83M-59.51M---58.33M-54.67M-49.46M-40.85M-57.01M--29.23M-30.14M-4.97M-2.87M
Investing Cash Flow -11.00K-186.00K-1.16M-1.56M-131.00K---551.00K-737.00K-459.00K-284.00K-9.78M--193.00K1.35M0-98.00K
Financing Cash Flow 49.77M31.43M84.31M48.98M54.54M---788.00K45.30M40.31M59.15M102.12M-6.37M-18.14M03.26M
Capital Expenditure -11.00K-186.00K-1.16M-1.56M-132.00K-193.00K-412.00K-551.00K-737.00K-459.00K-284.00K-9.78M-3.32M-216.00K-197.00K--98.00K
Free Cash Flow -12.30M-19.88M-39.99M-80.39M-59.64M---58.88M-55.41M-49.92M-41.14M-66.79M--29.45M-30.34M-4.97M-2.97M
Net Change in Cash --------------23.06M-46.93M-4.97M294.00K
Share Buybacks 380.00K1.67M274.00K546.00K498.00K544.00K34.00K2.00K01.62M653.00K-045.00K0--

Ratios (Annual)

Figures in %.

Metric Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----------------------
Operating Margin % --------10,704.6%-12,771.1%----2,409.4%-837.3%-36,921.9%----1,206.0%-569,860.0%-48,120.0%-84,500.0%
Net Margin % --------9,561.9%-12,016.5%----2,409.2%-850.3%-36,381.5%----1,291.2%-702,800.0%-46,790.0%-83,520.0%
ROE % 3,949.3%-132.1%-67.3%-87.6%-374.4%-27.2%-106.9%-89.1%-198.4%-115.6%-93.9%-137.4%213.8%56.1%-62.1%-124.0%-64.5%--97.9%-557.2%-226.8%-194.0%
ROCE % -------42.4%-75.4%-158.3%-90.2%-126.4%-88.6%-182.6%-63.1%-63.0%-59.9%-62.8%--86.4%-451.8%-233.3%-196.2%

Shareholding Pattern

Insiders
15.30%
Institutions
4.88%
Public Float
5.76%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 0.84% 21.35K $25.62K
2 Geode Capital Management, LLC 0.76% 19.36K $23.23K
3 Vanguard Fiduciary Trust Co 0.61% 15.50K $18.60K
4 Vanguard Capital Management LLC 0.55% 14.06K $16.88K
5 Citadel Advisors Llc 0.47% 11.87K $14.24K
6 Osaic Holdings Inc. 0.07% 1.73K $2.08K
7 Tower Research Capital LLC (TRC) 0.06% 1.62K $1.95K
8 Arax Advisory Partners 0.05% 1.22K $1.46K
9 UBS Group AG 0.04% 992 $1.19K
10 Morgan Stanley 0.03% 836 $1.00K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TCRT

Google News ue, 11 Aug 2026

Alaunos Therapeutics (TCRT) CEO granted 4,363 shares in lieu of cash salary - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOdkhCUi1ZOHM4LUNDSGxHazlja01lMHhqQkUzTzM0TU1LYmpCbnk0aW9DVXFyekh3MGNkMFlCd3FqbXJjWXA5QkNQX2EwdFBwcG5GOFNVaTQxLVZWMm1aN3FpTkw3ZUFGWVdvMWMzME5LTGxiMG1UeXdXUFBzUFRQQ012dkFZTTRfX2ZlTU…

Google News ue, 26 May 2026

TCRT - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE4zR2Uxdi1GN0dCUi1pRUJzRnQ5R3UtSXNQM3c3Y0tFZ1B1TXdWYldEaUJBNVVOX21PRlZkdmJVQTJxZm4zV1E?oc=5" target="_blank">TCRT</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News hu, 30 Jul 2026

Alaunos Therapeutics (TCRT) Shows Modest Decline Amid Tight Range Trading - Bearish Pattern Stocks - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQejFQXzd1QUZ4ODdWdTdPWGluNDlqUVA5N1FTOEtqTF9yc2N1UlpqVHI1XzgtalNrUFFVY2k5WXZPTFhqMHFtVGZXRmZDYWlTWVRRU0xBeEZJT0lMSnJMaDEwX3RobFVNeGxURDZuaVJ6dWYxd244Ul9QdXZEeTgyOGkyUm0xdkJIQTlrMF…

Google News ue, 26 May 2026

Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPa2piUWdQTW1zTGJnWE5DbHFYWVZKZ0FDZ2N1U1VWdW1ubVcyMzFFcWJVb0p0ZERRSHVaY3Y3RVF3SmN2cGxVSEJlVm1CTEVxWm1yZDVqQVdKcjR0MjQ2WTY1Wi1YMlZyQm9EeHB2MjFabkIxV2M1dDhUMmpabms4NVhZR0MwSlJ4Rzg4WU…

Google News Sun, 23 Aug 2026

Alaunos (TCRT) Latest: Moves 1.13% Lower to $1.76 on the Day; Price Setup: the Supplied Trading Band Runs From $1.67 to $1.85 on the Day - Strangle Setup - dars.gov.et

<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxOY0ZhV2NNZXA2WFBOYXU4WUFIUHFzOTlPc3dmOXBQeXJvemVvYXlwTk1kaktsMFl2cTRyTURwaktaVVdCdUFzSHBhVTh3cElZS3A4RWVpQ2VTYTNuYWw0TjZSYVV1U0RrdGJMRUF0R2h3MVBfOEx2R2ZTOU0tMVd5bzVXYVJTNktsdFF1OE…

Google News Wed, 27 Mar 2024

symbol__ Stock Quote Price and Forecast - CNN

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBBdnhwT1BOZjZFa0owUUxNVmc0dlN3RFJqenlOQVBveHlhWjFoMUNNb09QR0Z1dDF0Wm1QSU1YNjhlZWNPN0dQV0hBWUVlQ0pO?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a>&nbsp;&nbsp;<fon…

TCRT — Frequently Asked Questions

What is the current share price of Alaunos Therapeutics, Inc. (TCRT)?

As of 2026-09-19 21:16 PDT, Alaunos Therapeutics, Inc. (TCRT) trades at $1.57 on NasdaqCM. Its 52-week range is $1.57 to $4.36.

What is the market capitalisation of TCRT?

Alaunos Therapeutics, Inc. (TCRT) has a market capitalisation of $3.99M on NasdaqCM.

What is the P/E ratio of TCRT?

TCRT trades at a trailing price-to-earnings (P/E) ratio of -0.90. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.21.

Is TCRT a good stock to buy?

This page provides a data-driven analysis of Alaunos Therapeutics, Inc. (TCRT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space